Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Roland Blanqué (Romainville, France), Roland Blanque, Nicolas Desroy, Sonia Dupont, Céline Cottereaux, Alain Monjardet, Emanuelle Wakselman, Wendy Laenen, Vince Russell, Ellen Van der Aar, Reginald Brys, Bertrand Heckmann. Pharmacological profile and efficacy of GLPG1690, a novel ATX inhibitor for COPD treatment. Eur Respir J 2015; 46: Suppl. 59, 2129

Member's Comments

No comment yet.

Related content which might interest you: RP6503, a novel and selective PI3K δ/gamma inhibitor, potentiates the effect of steroids in pre-clinical models of COPD Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 CHI-91040, a novel inhaled p38α inhibitor, counteracts lung inflammation induced by IL-1β in the rat Source: International Congress 2016 – ILD: from the bench to the bedside Year: 2016 Pre-clinical to clinical potency of AZD7624 in LPS induced TNFa response Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD Year: 2015 In vitro pharmacological characterization of CHF6001, a novel selective phosphodiesterase 4 (PDE4) inhibitor with a robust anti-inflammatory profile Source: International Congress 2014 – Novel targets and drugs for asthma and COPD Year: 2014 In vivo efficacy of CHF6001, an inhaled PDE4 inhibitor with a wide therapeutic window Source: International Congress 2014 – Animal models in respiratory drug development Year: 2014 Favorable human safety, pharmacokinetics and pharmacodynamics of the autotaxin inhibitor GLPG1690, a potential new treatment in COPD Source: International Congress 2015 – Advances in the future treatment of COPD Year: 2015 Prediction of human lung PK for AZD7624, an inhaled P38 inhibitor for the treatment of COPD Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis Year: 2015 The effects of clinically relevant reference agents in a mouse model of severe asthma Source: International Congress 2015 – Advances in the future treatment of severe asthma Year: 2015 Preclinical characterization of CPL-302-201, a novel, highly potent and selective PI3Kδ inhibitor for the treatment of inflammatory disorders Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 The anti-inflammatory effects of PF03715455 and roflumilast on both cellular and tissue inflammation in a mouse model of COPD Source: Annual Congress 2013 –New drugs in respiratory medicine Year: 2013 LATE-BREAKING ABSTRACT: Inhibition of RC kinase is a novel therapeutic approach for the treatment of COPD and IPF Source: International Congress 2014 – Latest insights in airway diseases Year: 2014 BmTI-A, a serine protease inhibitor, reduces the chronic allergic lung inflammation in a mice model Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis Year: 2015 In vitro pharmacological characterization of a novel p38α (MAPK14) inhibitor designed for inhaled delivery Source: International Congress 2016 – Novel insights into the treatment of COPD Year: 2016 Additive anti-inflammatory effect of glucocorticoids and PDE4 inhibitors on COPD CD8 cells Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 The effects of intra-nasally administered anti-inflammatory compounds in a mouse model of acute COPD exacerbations Source: Annual Congress 2013 –Preclinical models for the development of new drugs for respiratory diseases Year: 2013 Redefining the asthma treatment paradigm using a locally administered dual PI3Kgd inhibitor Source: International Congress 2016 – New therapies and therapeutic targets Year: 2016 Anti-inflammatory effects of the novel phosphodiesterase type 4 inhibitor CHF6001 on COPD alveolar macrophages and lung tissue Source: International Congress 2014 – Novel targets and drugs for asthma and COPD Year: 2014 Pharmacological profile of a novel, potent and oral TRPA1 antagonist. Characterization in a preclinical model of induced cough Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis Year: 2015 In vitro and in vivo pharmacological profile of RP6503, a novel dual PI3K Δ/gamma inhibitor, in pulmonary disease systems Source: Annual Congress 2013 –Emerging new targets for the treatment of respiratory diseases Year: 2013 Efficacy of a novel PI3Kd inhibitor, DS-1515 in animal models of asthma Source: International Congress 2018 – Novel drug targets for asthma and COPD Year: 2018